Retatrutide 30mg — Triple Agonist Peptide for Research Use

Retatrutide is an advanced experimental peptide developed by Eli Lilly, designed as a once-weekly injectable. It is the first compound to simultaneously activate three key metabolic receptors: GLP-1, GIP, and Glucagon — making it a triple agonist with a unique mechanism of action.

How It Works

• GLP-1 Receptor: Reduces hunger signaling, increases satiety, delays gastric emptying, and improves insulin secretion — the same pathway targeted by Semaglutide.
• GIP Receptor: Improves insulin sensitivity, enhances glucose disposal, may reduce GLP-1-associated nausea, and helps preserve lean tissue during weight loss.
• Glucagon Receptor: Mobilizes stored energy, increases fat oxidation, promotes liver-fat reduction, and raises metabolic rate. GLP-1 and GIP activity offsets glucagon's tendency to raise blood glucose.

Clinical Research Highlights

• ~24% weight loss at 48 weeks in Phase 2 obesity studies
• ~28.3% weight loss at 80 weeks with 12mg in Phase 3 TRIUMPH-1
• ~45% of participants achieved ≥30% weight loss
• Significant reductions in visceral and liver fat
• Improved triglycerides, insulin sensitivity, and cardiometabolic markers

Retatrutide vs. Semaglutide vs. Tirzepatide

• Semaglutide: GLP-1 agonist — strong appetite suppression, moderate fat oxidation
• Tirzepatide: GLP-1 + GIP dual agonist — very strong appetite suppression, higher weight loss
• Retatrutide: GLP-1 + GIP + Glucagon triple agonist — highest reported weight loss, greatest fat oxidation studied to date

For research purposes only. Not intended for human use. This product is sold strictly for laboratory and scientific research.